Cosmetics Europe’s Director-General John Chave discusses “a whole clutch of errors and misunderstandings” underlying ECHA’s proposal to prohibit use of intentionally added microplastics in cosmetics. According to the exec, the agency overestimates the prevalence and promise of natural/organic formulation while underestimating compliance costs by as much as 50%.
Small and medium-sized enterprises rely less on microplastics than large cosmetics companies, as they tend to be more invested in natural/organic formulation, and thus stand to benefit from an EU-wide ban on intentionally added microplastics.
So says the European Chemicals Agency in its Jan. 30 proposal for a microplastics restriction under the Registration, Evaluation,...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
